三生国健:GJ-613新药上市申请获受理

美港电讯
05 Jun

【三生国健:GJ-613新药上市申请获受理】金十数据6月5日讯,三生国健公告,公司重组抗IL-1β人源化单克隆抗体注射液(项目代号“GJ-613”)用于急性痛风性关节炎适应症的III期临床试验达到了主要疗效双终点,并向国家药品监督管理局提交了新药上市申请。该药品为公司创新研发,拥有自主知识产权的抗IL-1β抗体,与已上市的同靶点产品Canakinumab和Gevokizumab具有完全不同的结合表位。已完成的III期临床研究显示,GJ-613在急性痛风性关节炎疼痛缓解和预防复发方面达到双主要疗效终点,与阳性对照药物复方倍他米松注射液的作用相当,并显著优于阳性对照药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10